VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Melisko on Duration of Aromatase Inhibitor Use in Breast Cancer

Michelle E. Melisko, MD
Published: Monday, Nov 20, 2017



Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), explains the discussion around duration of use of aromatase inhibitors (AIs) in patients who have estrogen receptor-positive breast cancer.

More than 10 years ago, it was established that continuing with an AI after tamoxifen was beneficial. MA.17R looked at the extension of an AI beyond 5 years, demonstrating an added benefit of an AI for 10 years—meeting its statistically significant endpoint.

The NSABP B-42 trial had a similar design, but these were patients who may not have had tamoxifen previously. There was a reduction in recurrences, but it did not meet the statistically significant endpoint.

 


Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), explains the discussion around duration of use of aromatase inhibitors (AIs) in patients who have estrogen receptor-positive breast cancer.

More than 10 years ago, it was established that continuing with an AI after tamoxifen was beneficial. MA.17R looked at the extension of an AI beyond 5 years, demonstrating an added benefit of an AI for 10 years—meeting its statistically significant endpoint.

The NSABP B-42 trial had a similar design, but these were patients who may not have had tamoxifen previously. There was a reduction in recurrences, but it did not meet the statistically significant endpoint.

 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x